ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ixekizumab

Also written as “Ixekizumab”, “LY2439821” and “80 mg ixekizumab”.

Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Spondylarthritis · Arthritis, Rheumatoid · Axial Spondyloarthritis, led by 3 companies.

Drug pageIxekizumab: every studyAll 56 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 4, 201738 company-led studies, 3 open or runningNext primary completion: Jun 9, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only361 open or runningphase 4since May 4, 2017Aug 25, 2009none ahead
Celltrionits history only11 open or runningphase 1since Sep 23, 2025Sep 23, 2025none ahead
Samsung Bioepis11 open or runningphase 1since Aug 20, 2026Aug 20, 2026Jun 9, 2027phase 1 · NCT07789964

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Samsung Bioepis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 20, 2026First study: phase 1 study in HealthyFirst studyNCT07789964 · 174 planned · South Korea

Ahead

  1. Jun 9, 2027Primary completion: phase 1 study in HealthyNCT07789964

TargetBeta

IL17A →read by rule
“Interleukin 17A inhibitor”ChEMBL 37, by rule

Other programs on IL17A

ProgramCompanyFurthest phaseStudies
secukinumabruleNovartisphase 4128
vunakizumabruleJiangsu HengRui Medicinephase 417
bimekizumabruleUCBphase 343
sonelokimabrulemoonlake-immunotherapeutics-agphase 312
simepdekinraEli Lillyphase 27
tibulizumabruleEli Lillyphase 25
SCT650CruleSinocelltech Groupphase 23
UA026ruleusynova-pharmaceuticals-ltdphase 11

Studies

The one study Samsung Bioepis leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07789964Healthy · South Korea1RecruitingJun 9, 2027174

How it is read

Names in the registry

  • “Ixekizumab”, 29 entries
  • “LY2439821”, 3 entries
  • “80 mg ixekizumab”, 2 entries
  • “Ixekizumab 80 mg Q4W”, 1 entry
  • “Ixekizumab 80 mg Q2W”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.